One‐stage and two‐stage designs for phase II clinical trials with survival endpoints

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Statistics in Medicine

• Publication date

  2014-09-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/sim.6196PMID 24817473
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time‐to‐event endpoints

  2015cited by this paper
• The design and analysis of sequential clinical trials

  2013cited by this paper
• Bayesian decision theoretic two‐stage design in phase II clinical trials with survival endpoint

  2012cited by this paper
• Group sequential trials revisited: Simple implementation using SAS

  2011cited by this paper
• Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.

  2011cited by this paper
• An exact method for analysis following a two‐stage phase II cancer clinical trial

  2010influential reference
• The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee

  2010cited by this paper
• Bayesian sample size for exploratory clinical trials incorporating historical data

  2008cited by this paper
• Designing phase II studies in cancer with time-to-event endpoints

  2008cited by this paper
• Monitoring event times in early phase clinical trials: some practical issues

  2005cited by this paper
• Design of Phase II cancer trials evaluating survival probabilities

  2003influential reference
• Optimal two-stage designs for phase ii clinical trials with differentiation of complete and partial responses

  2000cited by this paper
• Optimal three-stage designs for phase II cancer clinical trials.

  1997cited by this paper
• Group sequential designs for monitoring survival probabilities.

  1996cited by this paper
• Application of the triangular test to phase II cancer clinical trials.

  1990cited by this paper
• Optimal two-stage designs for phase II clinical trials.

  1989cited by this paper
• One-sample multiple testing procedure for phase II clinical trials.

  1982cited by this paper
• Rank Tests and a One-Sample Logrank Test for Comparing Observed Survival Data to a Standard Population

  1981cited by this paper
• Phase II clinical trials.

  1977cited by this paper
• The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent.

  1961cited by this paper
• THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

  1934cited by this paper

• Two-Stage Design Sample Size Determination for Two Doses in Oncology Phase II Trials

  2025cites this paper
• TMBserval: a statistical explainable learning model reveals weighted tumor mutation burden better categorizing therapeutic benefits

  2023cites this paper
• Sample size determination and evaluation for two-stage adaptive designs of single arm clinical trials based on median event time test

  2023cites this paper
• Two-stage optimal designs based on exact variance for a single-arm trial with survival endpoints

  2020cites this paper
• Point and interval estimation in two-stage adaptive designs with time to event data and biomarker-driven subpopulation selection

  2020cites this paper
• Two-stage optimal designs with survival endpoint when the follow-up time is restricted

  2019cites this paper
• Therapeutic Exploratory Trials

  2018cites this paper
• Cumulative References

  2018cites this paper
• A two-stage design for phase II trials with time-to-event endpoint using restricted follow-up

  2017cites this paper
• Modeling Arbitrarily Interval-Censored Survival Data with External Time-Dependent Covariates

  2015influential citation
• Mixed response and time-to-event endpoints for multistage single-arm phase II design

  2015cites this paper
• Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time‐to‐event endpoints

  2015cites this paper
• Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).

  2014cites this paper